AlphAIAlphAI — Financial news for AI agents
benzinga.comSEP 252 min read$MRNA

Moderna Stock Trends After Hours - Moderna (NASDAQ:MRNA), Merck & Co (NYSE:MRK)

Moderna (MRNA) shares rose 0.087% to $194.99 in after-hours trading, following a 6.98% gain during the regular session. The company announced that three abstracts on its investigational therapy, including a Phase 3 trial with Merck & Co.'s (MRK) pembrolizumab, were accepted for presentation at the European Society for Medical Oncology Congress 2026. MRNA has a market cap of $77.78 billion and a 52-week high of $195.71.

Original reporting
benzinga.com
Published Sep 25, 2026, 2:54 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 25, 2026, 3:03 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$MRNA
Bullish
medium confidence
Mentioned
$MRNA · $MRK
Relevance
5/10
AlphAI data visualization · based on benzinga.com
Decision brief

The 30-second read

$MRNABullishLow
01

Why it matters

The acceptance may generate short‑term buying interest but lacks substantive data to drive a significant move.

02

Market read

Moderna is the primary subject; the news is a modest catalyst with limited immediate trading impact.

03

What to watch

Potential competition from other mRNA oncology programs and regulatory timelines.

Relevance 5/10Novelty 5/10Timing: after-hours Thursday

Background

Moderna's mRNA‑based individualized neoantigen therapy is in early clinical stages; abstract acceptance indicates progress toward data disclosure at a major oncology conference.

Company-level read

Ticker impact

$MRNABullishMedium confidence
Context

Moderna announced three abstracts on its mRNA neoantigen therapy were accepted for presentation at the ESMO 2026 Congress.

Expected impact

Potential modest upside as investors price in upcoming data presentations.

Evidence & confidence

Abstract acceptance signals progress but no data released; impact limited to anticipation.

Market effects

Sector

Highlights ongoing activity in the biotech sector's mRNA oncology pipeline.

Regional

Limited to US biotech investors; no broader market effect.

Global

Modest, as abstract acceptance is an early‑stage signal.

Counterpoint

What could challenge this read

Without actual trial data, the abstract acceptance may be over‑hyped and price could stall.

Key entities

  • Company
    Moderna, Inc.

    Biotech firm developing mRNA therapies.

  • Company
    Merck & Co.

    Partner in the melanoma trial.

Read at source← All news

Related articles

SEP 25
$MRNAHighAI 9/10

Moderna’s mFlusiva Becomes First Approved mRNA Flu Vaccine Available in US

Moderna's mFlusiva, the first mRNA-based flu vaccine, is now available in the U.S. for people 50 and older. According to the company, it was 27% more effective than standard vaccines in clinical trials. The FDA approved it for ages 50-64 via the standard process and for 65+ via an accelerated process. Side effects were mostly mild and temporary.

mezha.net2 min
SEP 25
$MRKMedAI 8/10

Penn helped test a promising mRNA cancer vaccine. Here’s what the trial means for the field.

Merck and Moderna's mRNA cancer vaccine, intismeran autogene, showed positive results in a late-stage trial, extending survival time without cancer recurrence or spread. The vaccine, tested on melanoma patients, trains the immune system to target cancer cells. Full results will be presented at the 2026 European Society for Medical Oncology meeting. The trial involved 1,137 participants, with two-thirds receiving the vaccine alongside Keytruda, a standard immunotherapy.

inquirer.com3 min
SEP 25
$MRKMed

Bank of America has strong message for Merck stock investors

Bank of America (BAC) hosted investor meetings with Merck's (MRK) Chief Medical Officer, expressing confidence in Merck's pipeline. Keytruda, Merck's top-selling drug, faces patent expiration in 2028. Merck raised its 2026 revenue forecast to $66.3B-$67.3B. BofA maintained a Buy rating and $166 price target. Merck's sac-TMT lung cancer drug is a key focus, with trial results expected in October.

aol.com2 min
SEP 24
$MRKMedAI 8/10

How Eye Trial Success At Merck (MRK) Has Changed Its Investment Story

Merck (MRK) reported positive Phase 2b/3 trial results for its investigational antibody remigromig in treating diabetic macular edema, matching a standard treatment. The success could expand Merck's revenue mix into ophthalmology. Analysts note this fits Merck's strategy to diversify beyond oncology, but near-term catalysts remain in other areas. Merck projects US$75.1b revenue and US$22.4b earnings by 2029, with some analysts forecasting higher figures.

simplywall.st3 min